IFNG and myeloid sarcoma: The clinical utility of exogenous IFN-γ to treat MS was explored in a pilot study conducted in the late 1980’s in relapse-remitting MS (RRMS) patients, and it was found that in patients receiving intravenous IFN-γ, the disease appeared to be exacerbated [44].